| 1 Mortality |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.1 Ampicillin (treatment) versus untreated control group, oxytetracycline, chloramphenicol or erythromycin |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.14, 65.90] |
| 1.2 Aureomycin (treatment) versus chloramphenicol (control) |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.06, 16.09] |
| 2 Complete remission (clinical cure) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 2.1 Erythromycin estolate for 14 days (treatment) versus erythromycin ethylsuccinate for 14 days (control) |
1 |
189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.43 [1.16, 10.13] |
| 3 Clinical improvement (better condition) after one week |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 3.1 Trimethoprim/sulfamethoxazole (treatment) versus tetracycline (control) |
1 |
66 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.70, 1.83] |
| 4 Decreased frequency of cough |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 4.1 Erythromycin estolate for 14 days (treatment) versus erythromycin ethylsuccinate for 14 days (control) |
1 |
189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.90, 1.24] |
| 5 Presence of any sign or symptoms of whooping cough |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 Erythromycin estolate for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
168 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.96, 1.03] |
| 6 Microbiological eradication |
10 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6.1 Ampicillin (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 6.2 Oxytetracycline (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
17.0 [1.11, 259.87] |
| 6.3 Chloramphenicol (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
15.0 [0.97, 231.84] |
| 6.4 Erythromycin (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
19.0 [1.25, 287.92] |
| 6.5 Erythromycin estolate for 14 days (treatment) versus erythromycin ethylsuccinate for 14 days (control) |
1 |
190 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.95, 1.03] |
| 6.6 Erythromycin stearate for 7 days (treatment) versus co‐trimoxazole for 7 days (control) |
1 |
19 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.11 [0.65, 1.90] |
| 6.7 Erythromycin estolate for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.96, 1.03] |
| 6.8 Azithromycin (treatment) for 3 days versus erythromycin for 14 days (control) |
1 |
45 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.92, 1.16] |
| 6.9 Azithromycin (treatment) for 5 days versus erythromycin estolate for 10 days (control) |
1 |
106 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.96, 1.04] |
| 6.10 Clarithromycin for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
54 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.94, 1.17] |
| 6.11 Trimethoprim/sulphamethoxazole for 7 days (treatment) versus tetracycline (control) for 7 days |
1 |
66 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.94, 1.06] |
| 6.12 Sulfadiazine/trimethoprim for 6 days (treatment) versus chloramphenicol for 6 days (control) |
1 |
33 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.67, 1.26] |
| 6.13 Ampicillin (treatment) versus chloramphenicol (control) |
1 |
95 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.65, 1.03] |
| 7 Bacteriological relapse |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7.1 Ampicillin (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.26, 3.81] |
| 7.2 Oxytetracycline (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.04, 2.69] |
| 7.3 Chloramphenicol (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.26, 3.81] |
| 7.4 Erythromycin (treatment) versus untreated group (control) |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.04, 2.69] |
| 7.5 Erythromycin estolate for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
155 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.45 [0.14, 83.44] |
| 7.6 Azithromycin (treatment) for 5 days versus erythromycin estolate for 10 days (control) |
1 |
104 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 8 Respiratory complications |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 8.1 Aureomycin (treatment) versus chloramphenicol (control) |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.43 [0.47, 4.35] |
| 9 Complications (otitis media) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.1 Clarithromycin for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.08 [0.00, 1.36] |
| 10 All side effects |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 10.1 Erythromycin estolate for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
168 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.51, 1.12] |
| 10.2 Azithromycin (treatment) for 3 days versus erythromycin for 14 days (control) |
1 |
122 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.38 [0.19, 0.75] |
| 10.3 Clarithromycin for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.53, 0.97] |
| 10.4 Ampicillin for 6 days (treatment) versus chloramphenicol for 6 days (control) |
1 |
148 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.81 [0.94, 3.48] |
| 10.5 Erythromycin estolate for 14 days (treatment) versus erythromycin ethylsuccinate for 14 days (control) |
1 |
190 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.35, 1.46] |
| 10.6 Aureomycin (chlortetracycline) (treatment) versus chloramphenicol (control) |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.63, 2.58] |
| 11 Gastro‐intestinal system side effects |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 11.1 Clarithromycin for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.47, 1.08] |
| 11.2 Azithromycin (treatment) for 5 days versus erythromycin estolate for 10 days (control) |
1 |
477 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.46 [0.34, 0.62] |
| 12 Side effects (diarrhoea) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 12.1 Erythromycin stearate for 7 days (treatment) versus co‐trimoxazole for 7 days (control) |
1 |
22 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.4 [0.25, 22.75] |
| 13 Compliance (detected by antimicrobial activity in urine) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 13.1 Erythromycin estolate for 14 days (treatment) versus erythromycin ethylsuccinate for 14 days (control) |
1 |
108 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.69, 0.94] |
| 14 Compliance (presented as number of children who took 100% of prescribed doses) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 14.1 Azithromycin (treatment) for 5 days versus erythromycin estolate for 10 days (control) |
1 |
477 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.63 [1.45, 1.85] |
| 15 Compliance (presented as percentage of drugs taken) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.1 Clarithromycin for 7 days (treatment) versus erythromycin estolate for 14 days (control) |
1 |
200 |
Mean Difference (IV, Fixed, 95% CI) |
9.90 [5.34, 14.46] |
